Regeneron Pharmaceuticals (REGN) Equity Average (2009 - 2026)

Regeneron Pharmaceuticals has reported Equity Average for 18 years, with the latest figure at $31.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 6.71% year-over-year to $31.3 billion; the trailing twelve-month figure through Mar 2026 stood at $31.3 billion (up 6.71% YoY), and the FY2025 full-year result was $30.3 billion, up 9.55% from the prior year.
• Equity Average for Q1 2026 stood at $31.3 billion, up from $31.1 billion in the prior quarter.
• The five-year high for Equity Average was $31.3 billion in Q1 2026, with the low at $19.3 billion in Q1 2022.
• Average Equity Average over 5 years is $26.1 billion, with a median of $26.5 billion recorded in 2024.
• Year-over-year, Equity Average soared 68.17% in 2022 and gained 5.85% in 2025.
• Tracing REGN's Equity Average over 5 years: stood at $22.1 billion in 2022, then rose by 15.36% to $25.4 billion in 2023, then rose by 15.33% to $29.3 billion in 2024, then increased by 6.02% to $31.1 billion in 2025, then advanced by 0.75% to $31.3 billion in 2026.
• The last three Equity Average figures came in at $31.3 billion (Q1 2026), $31.1 billion (Q4 2025), and $30.4 billion (Q3 2025), per Business Quant data.

Peer Comparison